ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 40.27
+0.78 (1.98%)
At close: Sep 25, 2026
ANG Lifesciences India Financials Overview
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 835.87 | 928.93 | 928.47 | 1,461 | 2,199 | 3,543 |
Revenue Growth | -15.60% | 0.05% | -36.45% | -33.55% | -37.94% | 129.50% |
Gross Profit Gross Profit Growth | 274.14 | 309.17 | 332.24 | 509.97 | 693.01 | 1,263 |
Operating Income Operating Income Growth | -76.34 | -50.84 | -68.47 | 13.78 | 134.63 | 618.6 |
Net Income Net Income Growth | -133.23 | -110.85 | -124.13 | -101.43 | -2.62 | 403.17 |
Earnings Per Share EPS Growth | -10.22 | -8.49 | -9.51 | -7.77 | -0.20 | 31.11 |
EPS Growth | - | - | - | - | - | 473.69% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Pharmaceuticals Pharmaceuticals Growth | 810.31 | 916.05 | 899.1 | 1,314 | 2,070 | 3,487 |
Printing and Packagings Printing and Packagings Growth | 66.38 | 48.62 | 67.63 | 183.02 | 242.05 | 218.97 |
Inter Segment Inter Segment Growth | -40.82 | -35.74 | -38.27 | -35.61 | -113.19 | -162.65 |
Total Total Growth | 835.87 | 928.93 | 928.47 | 1,461 | 2,199 | 3,543 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 37.89 | 37.89 | 36.36 | 57.35 | 61.78 | 66.52 |
Total Debt Total Debt Growth | 793.99 | 793.99 | 832.06 | 728.37 | 707.48 | 769.95 |
Net Cash (Debt) Net Cash Growth | -756.1 | -756.1 | -795.71 | -671.01 | -645.71 | -703.43 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -58.01 | -57.90 | -60.93 | -51.39 | -49.70 | -54.28 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | - | 110.3 | -2.55 | -94.95 | 263.77 | 247.17 |
Capital Expenditures CapEx Growth | - | -4.39 | -37.51 | -55.69 | -104.45 | -413.45 |
Free Cash Flow Free Cash Flow Growth | - | 105.91 | -40.07 | -150.63 | 159.33 | -166.28 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 32.80% | 33.28% | 35.78% | 34.90% | 31.52% | 35.65% |
Operating Margin | -9.13% | -5.47% | -7.37% | 0.94% | 6.12% | 17.46% |
Pretax Margin | -18.97% | -14.01% | -16.91% | -7.33% | 1.19% | 15.10% |
Profit Margin | -15.94% | -11.93% | -13.37% | -6.94% | -0.12% | 11.38% |
FCF Margin | - | 11.40% | -4.32% | -10.31% | 7.25% | -4.69% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 28, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | - | - | - | 6.03 |
P/FCF Ratio | 4.97 | 2.27 | - | - | 6.23 | - |
PS Ratio | 0.63 | 0.26 | 0.32 | 0.40 | 0.45 | 0.69 |